SCHEMBL138484

SCHEMBL138484

Cn1c(=O)c(C(=O)c2ccccc2)c2c3c(c(Nc4ccccc4)ccc31)C(=O)c1ccccc1-2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 4/20 0.65
PABPC1 P11940 3/20 0.54
MAPT P10636 10/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
NR4A1 P22736 1/20 0.51
MEN1 O00255 12/20 0.49
KMT2A Q03164 12/20 0.49
POLB P06746 6/20 0.49
L3MBTL1 Q9Y468 4/20 0.49
USP2 O75604 6/20 0.44
MAPK1 P28482 3/20 0.44
GAA P10253 3/20 0.44
HPGD P15428 2/20 0.44
BLM P54132 2/20 0.44
PKM P14618 1/20 0.44
CYP1A2 P05177 2/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 1/20 0.43
KEAP1 Q14145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14559159 0.95 MAP3K5 (0.61) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL10033596 0.91 MAP3K5 (0.57) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL17808464 0.90 MAP3K5 (0.56) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL10098484 0.90 MAP3K5 (0.59) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL966625 0.90 MAP3K5 (0.58) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL20682157 0.87 MAP3K5 (0.59) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL17813950 0.85 MAP3K5 (0.57) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL13382720 0.85 MEN1 (0.66) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL11891998 0.84 MAP3K5 (0.52) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1
SCHEMBL17808610 0.84 MAP3K5 (0.49) MAP3K5PABPC1MAPTSMN1; SMN2NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160160065-A1 INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2016-06-09 US disclosed
US-20120056931-A1 MAGENTA COLORING MATTER, INK COMPOSITION, AND COLORED BODY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2012-03-08 US disclosed
US-20120056931-A1 MAGENTA COLORING MATTER, INK COMPOSITION, AND COLORED BODY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2012-03-08 US disclosed
US-20110195238-A1 ANTHRAPYRIDONE COLORING MATTER, SALT THEREOF, INK COMPOSITION AND COLORED BODY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-08-11 US disclosed
US-20110195238-A1 ANTHRAPYRIDONE COLORING MATTER, SALT THEREOF, INK COMPOSITION AND COLORED BODY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-08-11 US disclosed
US-7909926-B2 Ink composition and colored product NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-03-22 US disclosed
US-7909926-B2 Ink composition and colored product NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-03-22 US disclosed
US-20090324900-A1 INK COMPOSITION AND COLORED PRODUCT NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-12-31 US disclosed
US-20090324900-A1 INK COMPOSITION AND COLORED PRODUCT NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195238-A1 ANTHRAPYRIDONE COLORING MATTER, SALT THEREOF, INK COMPOSITION AND COLORED BODY XDH, HAX1, ANXA1 MAP3K5 2261/4885PABPC1 1264/4885MAPT 2210/4885
US-20090324900-A1 INK COMPOSITION AND COLORED PRODUCT ATXN2, IK, AURKA MAP3K5 67/4885PABPC1 1856/4885MAPT 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.